ST Shuangcheng (002693.SZ): Injection-grade bortezomib ANDA obtained US FDA market approval.

Update from the Wise Finance APP, *ST Shuangcheng (002693.SZ) announced that the company has recently received a notification from the U.S. Food and Drug Administration (FDA), stating that the Abbreviated New Drug Application (ANDA) for injectable bortezomib submitted by the company to the U.S. FDA has been approved. The U.S. FDA conducted a comprehensive technical review of the company's submission for injectable bortezomib ANDA and determined that the company's product is bioequivalent and therapeutically equivalent to the reference drug.